Poinciana Advisors Group LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 3,212 shares of the biopharmaceutical company’s stock, valued at approximately $297,000.
Other hedge funds have also recently modified their holdings of the company. Greatmark Investment Partners Inc. raised its holdings in shares of Gilead Sciences by 1.9% in the 4th quarter. Greatmark Investment Partners Inc. now owns 33,032 shares of the biopharmaceutical company’s stock worth $3,051,000 after purchasing an additional 620 shares during the period. Postrock Partners LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $248,000. Wellington Shields Capital Management LLC raised its holdings in shares of Gilead Sciences by 3,757.7% in the 4th quarter. Wellington Shields Capital Management LLC now owns 234,507 shares of the biopharmaceutical company’s stock worth $21,661,000 after purchasing an additional 228,428 shares during the period. Atala Financial Inc bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $188,000. Finally, LBP AM SA raised its holdings in shares of Gilead Sciences by 41.1% in the 4th quarter. LBP AM SA now owns 212,835 shares of the biopharmaceutical company’s stock worth $19,660,000 after purchasing an additional 61,948 shares during the period. Institutional investors own 83.67% of the company’s stock.
Gilead Sciences Price Performance
Shares of NASDAQ:GILD opened at $111.44 on Friday. The company’s fifty day moving average price is $101.82 and its 200-day moving average price is $92.71. The firm has a market capitalization of $138.78 billion, a price-to-earnings ratio of 301.19, a PEG ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.
Gilead Sciences Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.84%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.
Insider Activity at Gilead Sciences
In related news, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the transaction, the chief financial officer now owns 169,061 shares of the company’s stock, valued at approximately $19,977,938.37. This trade represents a 9.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 311,285 shares of company stock valued at $31,284,910. Insiders own 0.16% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on GILD shares. Royal Bank of Canada lifted their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. The Goldman Sachs Group raised their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Finally, DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a report on Thursday, February 13th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $104.52.
Check Out Our Latest Stock Report on GILD
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
- Five stocks we like better than Gilead Sciences
- Best Stocks Under $10.00
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- The 3 Best Retail Stocks to Shop for in August
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- How to Calculate Return on Investment (ROI)
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.